N-Myristoyltransferase 1, NMT, Myristoyl-CoA:Protein N-Myristoyltransferase 1, Type I N-Myristoyltransferase, EC 2.3.1.97, Myristoyl-CoA:Protein,N- Myristoyltransferase, Glycylpeptide N-Tetradecanoyltransferase 1,Peptide N-Myristoyltransferase 1,Alternative, Short Form NMT-S, Short Form NMT-S,Long Form, NMT-L, Alternative, Long Form, NMT-L, NMT 1.
NMT1 antibody was purified from mouse ascitic fluids by protein-A affinity chromatography.
PAT2C8AT.
Anti-human NMT1 mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human NMT1 amino acids 1-496 purified from E. coli.
Mouse IgG2a heavy chain and κ light chain.
NMT1 (N-myristoyltransferase 1) is an essential enzyme responsible for catalyzing the transfer of myristate from CoA to proteins. It facilitates N-myristoylation, a critical post-translational modification where myristate, a 14-carbon saturated fatty acid, is attached via an amide linkage to the N-terminal glycine residue of numerous cellular and viral proteins . This modification is irreversible and crucial for the proper biological functioning of many myristoylated proteins, including components of signal transduction pathways such as the alpha subunit of G protein GO (GNAO1) . Recent research has shown that NMT1 plays pivotal roles in tumorigenesis, particularly in liver cancer development, making it an important research target for understanding cancer mechanisms .
NMT1 protein has the following key characteristics:
Full Name: N-myristoyltransferase 1 (also known by synonyms including NMT-S, NMT-L)
Calculated Molecular Weight: 496 amino acids, approximately 57 kDa
Observed Molecular Weight: 50-60 kDa in experimental conditions
Primary Function: Transfer of myristate from CoA to proteins with N-terminal glycine residues
NMT1 antibodies are versatile tools employed in multiple research applications:
The antibodies have demonstrated reactivity with human, mouse, and rat samples, making them suitable for comparative studies across species .
Researchers can employ several sophisticated techniques to assess NMT1-dependent protein myristoylation:
Click Chemistry Assay: This method enables detection of myristoylated proteins by using alkyne-tagged myristoyl-CoA analogs (e.g., Alk12-CoA). The protocol involves:
Treating cells with the NMT1/NMT2 inhibitor DDD85646 to control background myristoylation
Expression and purification of target proteins
In vitro modification with recombinant NMT1 and Alk12-CoA
Conjugation of an azide-containing fluorescent dye to the alkyne tag via click chemistry
Metabolic Labeling: Cells are incubated with azido-myristate, followed by cell lysis, click chemistry reaction with alkyne-TAMRA, and visualization of myristoylated proteins by Western blot using anti-TAMRA antibodies .
Protein Ligation Assay (PLA): This technique can identify direct interactions between NMT1 and target proteins:
Validating NMT1 antibody specificity is crucial for reliable experimental results. Recommended validation strategies include:
Genetic Knockdown/Knockout Controls:
Liver-Specific Knockout Model: For in vivo research, liver-conditional NMT1 knockout mice (NMT1 flox/flox: Alb-Cre) provide an excellent system to validate antibody specificity and study NMT1 function:
Multiple Detection Methods: Confirm findings using orthogonal techniques:
Compare immunohistochemistry results with Western blot data
Validate with immunoprecipitation followed by mass spectrometry
Recent research has elucidated NMT1's critical role in liver cancer development:
Expression Pattern: NMT1 shows elevated expression in liver cancer tissues compared to adjacent normal tissues, suggesting its potential as a biomarker .
Functional Impact: Liver-specific NMT1 knockout mice (NMT1 flox/flox: Alb-Cre) exhibit reduced tumorigenesis in DEN/CCl4-induced liver cancer models, demonstrating that NMT1 is essential for liver tumor development .
Mechanistic Insights: NMT1 mediates its oncogenic effects through:
Experimental Approaches: Researchers investigating NMT1 in liver cancer typically employ:
Understanding the differences between NMT1 and NMT2 is essential for proper experimental design:
Enzymatic Activities:
Both NMT1 and NMT2 can myristoylate N-terminal glycine residues
Remarkably, both enzymes can also myristoylate specific lysine residues, representing a novel type of protein modification
In vitro studies using recombinant enzymes show that both can modify substrates like ARF6, including both G2 (glycine) and K3 (lysine) sites
Experimental Distinction:
Use specific antibodies: anti-NMT1 (such as Abcam #ab186123) and anti-NMT2 (Abcam #ab224045)
Apply selective knockdown: NMT1-1 siRNA and NMT2-4 siRNA produce distinct effects on protein expression patterns
Conditional knockout models: NMT1 flox/flox: Alb-Cre mice provide specific insights into NMT1 function without affecting NMT2
Functional Redundancy: When designing experiments targeting either enzyme, consider potential compensatory mechanisms between NMT1 and NMT2.
Proper handling ensures antibody integrity and experimental reproducibility:
Click chemistry has revolutionized the study of NMT1 and protein myristoylation through:
Substrate Detection Protocol:
Cells are treated with myristic acid analog containing an alkyne group (e.g., YnMyr)
After cell lysis, the click chemistry reaction attaches an azide-containing tag to myristoylated proteins
The click reaction mixture typically includes CuSO4 (1 mM), TCEP (1 mM), and TBTA (0.1 mM)
After protein precipitation with methanol containing EDTA (10 mM), proteins are resuspended in sample buffer
Analysis by Western blot using antibodies against the tag (e.g., anti-TAMRA)
Advantages Over Traditional Methods:
Rigorous experimental controls are crucial for reliable NMT1 research in cancer models:
Genetic Controls:
Pharmacological Controls:
Tissue Controls:
Several techniques can elucidate NMT1-substrate interactions:
Co-Immunoprecipitation (Co-IP):
Protein Ligation Assay (PLA):
In Vitro Myristoylation Assays:
Inconsistent staining is a common challenge when working with NMT1 antibodies. Methodological solutions include:
Optimization of Antigen Retrieval:
Antibody Validation:
Sample Preparation Considerations:
While NMT1's role in cancer is well-documented, research is expanding into other areas:
Infectious Disease Applications:
Cellular Signaling Research:
Developmental Biology:
Proteomics offers powerful tools for comprehensive identification of NMT1 substrates:
iTraq-Based Approaches:
Click Chemistry-Coupled Proteomics:
Parallel Reaction Monitoring (PRM):
By implementing these advanced approaches and considering the methodological details provided, researchers can design robust experiments to investigate NMT1 function and its implications in various biological contexts.
N-Myristoyltransferase 1 (NMT1) is an enzyme that plays a crucial role in the process of protein myristoylation, a type of lipid modification where the fatty acid myristate is covalently attached to the N-terminal glycine of target proteins. This modification is essential for the proper functioning of various proteins involved in signal transduction, cell proliferation, and apoptosis.
NMT1 is essential for the viability and development of organisms. Studies have shown that NMT1-deficient mice exhibit severe developmental defects and do not survive beyond early embryonic stages . This highlights the enzyme’s critical role in early development. Additionally, NMT1 has been implicated in various diseases, including cancer and viral infections. For instance, NMT1 activity is required for the production of infectious human immunodeficiency virus type 1 (HIV-1), making it a potential target for antiviral therapies .
Given its essential role in cell viability and disease processes, NMT1 has garnered interest as a therapeutic target. Inhibitors of NMT1 have shown promise in preclinical studies for the treatment of cancer and infectious diseases. For example, inhibition of NMT1 in lung carcinoma cells leads to mitochondrial iron overload and cell death, suggesting its potential as a cancer therapeutic target .